
CLAIMS

1. Use of a compound in the manufacture of a medicament for the treatment of lung adenocarcinoma in a patient subsequent to another form of treatment selected from cisplatin, gemcitabine, docetaxel, and crizotinib treatment, wherein the compound is the malate salt of compound 1:




Compound 1

wherein the lung adenocarcinoma is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer.

2. The use according to claim 1, wherein the compound is the (L)- or (D)-malate salt of compound 1.


3. Use of a compound in the manufacture of a medicament for the treatment of a ROS1 fusion-positive non-small cell lung cancer in a patient subsequent to another form of treatment selected from cisplatin, gemcitabine, docetaxel, and crizotinib treatment, wherein the compound is the L-malate salt of compound 1:



Compound 1

wherein the lung cancer is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer.

4. Use of a compound in the manufacture of a medicament for inhibiting or reversing the progress of cancer mediated by ROS1 kinase in a mammal subsequent to another form of treatment selected from cisplatin, gemcitabine, docetaxel, and crizotinib treatment, wherein the compound is the L-malate salt of compound 1:




Compound 1

wherein the cancer is SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer.

5. The use according to any of claims 1-4, wherein detection of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using a FISH, CISH or SISH assay; or wherein detection of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using any form of genome

PCR, direct sequencing, PCR sequencing, RT-PCR or similar assay; or wherein detection of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using an antibody which specifically binds to SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion polypeptide or a fragment thereof.

6. Use of a compound in the manufacture of a medicament for the diagnosis and treatment of a patient who has received prior treatment selected from cisplatin, gemcitabine, docetaxel, and crizotinib treatment, wherein the patient has a NSCLC tumor and the tumor is identified as SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive NSCLC, wherein the compound is the L-malate salt of compound 1:



Compound 1.

7. The use according to claim 6, wherein identification of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using a FISH, CISH or SISH assay; or wherein identification of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using any form of genome PCR, direct sequencing, PCR sequencing, RT-PCR or similar assay; or wherein identification of the SLC34A2-ROS1, CD74-ROS1, or FIG-ROS1 fusion-positive non-small cell lung cancer is made using an antibody which specifically binds to SLC34A2-ROS1,

CD74-ROS1, or FIG-ROS1 fusion polypeptide or a fragment thereof.

8. The use according to any preceding claim, wherein the compound produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in metastasis, complete remission, partial remission, stable disease, increase in overall response rate, and a pathologic complete response.